Please login to the form below

Not currently logged in
Email:
Password:

malaria

This page shows the latest malaria news and features for those working in and with pharma, biotech and healthcare.

Novartis’ Egatan gains US approval for neglected tropical disease

Novartis’ Egatan gains US approval for neglected tropical disease

Novartis has a long-standing commitment to addressing global health challenges and supporting disease elimination efforts, in diseases such as leprosy, malaria and fascioliasis,” said Vas Narasimhan, CEO of Novartis (below).

Latest news

  • Evotec says Sanofi deal makes it anti-infectives powerhouse Evotec says Sanofi deal makes it anti-infectives powerhouse

    regulatory approvals of course – and that will give it “the highest qualified translational footprint in infectious disease research globally.” It will focus initially on antimicrobial resistant (AMR) infections, tuberculosis, and malaria,

  • Gates’ non-profit biotech for poverty diseases sets out its stall at BIO Gates’ non-profit biotech for poverty diseases sets out its stall at BIO

    number of avoidable deaths each year - 1.7m in the case of TB and around half a million apiece from malaria and diarrhoea/enteric diseases. ... Previously, Heaton served as director of the vaccine development and surveillance team at the Gates Foundation,

  • GSK cues up regulatory filings for relapsing malaria drug GSK cues up regulatory filings for relapsing malaria drug

    One of the greatest challenges for patients with P vivax malaria is preventing relapses," said GSK's president of R&D Patrick Vallance. ... The vaccine targets P falciparum, the most deadly malaria parasite globally and the most prevalent form in Africa.

  • Dosing of GSK's malaria vaccine due to start in 2018 Dosing of GSK's malaria vaccine due to start in 2018

    RTS, S, acts against Plasmodium falciparum, the most deadly malaria parasite globally and the most prevalent in Africa. ... a "very meaningful contribution to controlling the impact of malaria on children in those African communities that need it the most

  • Malaria vaccine is first to provide 'sustained protection' Malaria vaccine is first to provide 'sustained protection'

    Intravenous injections were shown to protect against exposure to malaria-infected mosquitoes in nine out of 14 (55%) recipients after 21 weeks. . ... Nevertheless, the NIAID's director Anthony Fauci said the study is "an encouraging step forward in our

More from news
Approximately 17 fully matching, plus 95 partially matching documents found.

Latest Intelligence

  • Waking the sleeping giant Waking the sleeping giant

    In Uganda, a malaria-specific app provides questions and answers relating to that disease, while in Mozambique another app greatly increases the efficacy of immunisation programmes by reminding users via text

  • The three forces behind the re-imagining of patient care The three forces behind the re-imagining of patient care

    developing a device that can detect malaria and give you a result in two minutes.

  • Aiming high for women Aiming high for women

    6. Halt and start to reverse the spread and incidence of HIV/AIDS, malaria and other diseases - MISSED, although the number of new HIV/AIDS infections fell by 40% in

  • Deal Watch February 2016 Deal Watch February 2016

    Alere has annual sales of approximately $2.5bn from a portfolio of point-of-care products in areas including cardiometabolic, infectious diseases such as HIV, malaria, syphilis, E. ... acquisition - company. 7, 200. Alere/Abbott Laboratories. portfolio

  • Amazing Africa Amazing Africa

    HIV/AIDS, malaria, famine, Ebola: there is a reason why the World Health Organization (WHO) considers it to be the region confronting the most dramatic public health crisis across the globe.

More from intelligence
Approximately 0 fully matching, plus 13 partially matching documents found.

Latest appointments

  • Former PEPFAR head Mark Dybul to lead the Global Fund Former PEPFAR head Mark Dybul to lead the Global Fund

    Joins at time of change for the AIDS, tuberculosis and malaria focused non-profit organisation. ... The Global Fund to Fight AIDS, Tuberculosis and Malaria has appointed renowned AIDS expert Dr Mark Dybul as executive director.

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics